May 05, 2016.
The Cell and Gene Therapy Catapult's survey of GMP cell and gene therapy manufacturing facilities in the UK highlights a number of key changes in the cell and gene therapy manufacturing landscape over the last 12 months, including:
Keith Thompson, CEO at the Cell and Gene Therapy Catapult, commented: “The data in the 2016 report shows growth across all the markers that we analyse and forecasts a considerable increase again in the next 12 months."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.